Cancer related antigens BST-2 (126-134)

Cancer related antigens BST-2 (126-134) is a synthetic peptide fragment derived from the bone marrow stromal antigen 2 (BST-2), also known as tetherin or CD317. This peptide corresponds to amino acid residues 126 to 134 of the BST-2 protein, a membrane-associated glycoprotein that plays a significant role in immune regulation and cellular signaling. BST-2 is highly relevant in cancer biology due to its involvement in tumor progression, immune escape mechanisms, and cellular interactions within the tumor microenvironment. The 126-134 sequence represents a defined epitope region, making it especially valuable for research into antigen presentation, immune recognition, and cancer immunology.

Epitope mapping: The 126-134 peptide sequence of BST-2 serves as a precise tool for identifying and characterizing immunogenic epitopes recognized by T cells or antibodies in cancer-related studies. Researchers utilize this peptide to assess immune responses against BST-2-derived antigens, enabling the delineation of specific regions involved in immune surveillance and tumor immune evasion. Such mapping is essential for understanding the molecular basis of antigenicity and for the rational design of immunological assays.

Antibody validation: The synthetic peptide corresponding to BST-2 (126-134) is frequently employed as a reference antigen in the validation and specificity testing of anti-BST-2 antibodies. By providing a well-defined linear epitope, it supports the development of highly selective monoclonal or polyclonal antibodies. These antibodies are critical for downstream applications such as immunohistochemistry, western blotting, and flow cytometry, especially in the context of cancer tissue analysis.

Cancer immunology research: Within the field of tumor immunology, the BST-2 (126-134) peptide is instrumental in studying the mechanisms by which cancer cells modulate immune responses. It is used to investigate the presentation of tumor-associated antigens on major histocompatibility complex (MHC) molecules and to evaluate the activation potential of cytotoxic T lymphocytes or other immune effector cells. Insights gained from such studies contribute to the broader understanding of tumor-immune system interactions and inform the development of immunotherapeutic approaches.

Peptide-based assay development: The defined nature of the BST-2 (126-134) fragment allows for its integration into various peptide-based assays, including enzyme-linked immunosorbent assays (ELISA) and T cell activation assays. These applications facilitate the quantitative measurement of antigen-specific immune responses, the screening of patient samples for immune reactivity, and the monitoring of immune status in experimental cancer models. The peptide's stability and sequence specificity make it an ideal candidate for assay standardization and reproducibility.

Peptide synthesis and modification studies: As a representative segment of the BST-2 protein, the 126-134 peptide serves as a model substrate for peptide synthesis optimization and structure-activity relationship investigations. Researchers may use it to explore post-translational modifications, such as phosphorylation or glycosylation, and to assess their effects on antigenicity and immune recognition. Such studies are vital for advancing peptide chemistry and for the design of novel peptide-based research tools in cancer biology.

1. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

2. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

3. High fat diet and GLP-1 drugs induce pancreatic injury in mice

4. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes